

PSJ3

Exhibit 20

Publix Meeting-NACDS

Introductions

1) Going Direct Program

- are there future plans of adding a CII vault?
- are you willing to explore non-CII products?
- have you discussed this opportunity with Qualitest?
- we are not capable of utilizing our UPS hub to ship CII's at this time
- next steps going forward?

2) Order Shortages

- Have you been able to resolve your latest shipment shortage from McKesson for Endo's products?
- has the SOM impacted your service levels from McKesson?

3) Regional Sales Opportunity

- as previously discussed is Publix still requiring any communications from Endo be directed thru your department and you'll disseminate the information and forward to your Regional Supervisors?
- are there any new marketing opportunities available for us to partner in communicating to your pharmacists?

4) Market Dynamics within the states you service

- any changes with regard to CII's in the five states you service?
- relationships with wholesalers
- SOM impact on business?
- have you received guidance from DEA?
- how do you interpret into policy?
- patient access issues?
- how do we help set expectations for patients and physicians?
- how can we ensure legitimate patients and providers have access to appropriate therapy?

5) Generic Lidoderm

- point of clarification on the potential launch date is **September 2013**

6) Questions?